Literature DB >> 7791168

Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis.

D Scholes1, A Stergachis, P M Penna, E H Normand, P D Hansten.   

Abstract

OBJECTIVE: To determine whether discontinuation patterns differed among nonsteroidal antiinflammatory drugs (NSAID) prescribed to treat osteoarthritis (OA).
METHODS: In a retrospective cohort study of Health Maintenance Organization enrollees, 1405 patients with OA aged 45 and older who received a new prescription for one of 4 NSAID were followed for 12 months. Survival analysis was used to evaluate time to discontinuation, used here as a relative measure of both drug efficacy and tolerability.
RESULTS: Rates of NSAID discontinuation during the study period were high; only 15 to 20% of those started on a study NSAID were still using the same drug at the end of the 12 month followup period. Using a proportional hazards model to adjust for covariates, the risk of discontinuation did not differ when comparing the agent with the longest duration of use, piroxicam (the referent), to enteric coated aspirin [relative risk (RR) 1.10, 95% confidence interval (CI) 0.93 to 1.30]. Adjusted rates of discontinuation were significantly higher for ibuprofen (RR 1.43, 95% CI 1.22 to 1.69) and for naproxen (RR 1.40, 95% CI 1.19 to 1.65) when compared to piroxicam.
CONCLUSION: NSAID discontinuation rates are high among patients with OA and risk of discontinuation differed between NSAID, even after controlling for the effects of such variables as age, disease severity, and concomitant therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7791168

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  Non-surgical treatment of osteoarthritis: a half century of "advances".

Authors:  K D Brandt
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

2.  Key questions concerning paracetamol and NSAIDs for osteoarthritis.

Authors:  P Courtney; M Doherty
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

3.  Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs.

Authors:  F Peris; E Martínez; X Badia; M Brosa
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada.

Authors:  R A Zabinski; T A Burke; J Johnson; F Lavoie; C Fitzsimon; R Tretiak; J V Chancellor
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  Racial differences in analgesic/anti-inflammatory medication use and perceptions of efficacy.

Authors:  Kelli L Dominick; Hayden B Bosworth; Jason B Hsieh; Barry K Moser
Journal:  J Natl Med Assoc       Date:  2004-07       Impact factor: 1.798

6.  Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration.

Authors:  E Losina; G Michl; J E Collins; D J Hunter; J M Jordan; E Yelin; A D Paltiel; J N Katz
Journal:  Osteoarthritis Cartilage       Date:  2015-12-31       Impact factor: 6.576

7.  Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation.

Authors:  E Losina; I M Usiskin; S R Smith; J K Sullivan; K C Smith; D J Hunter; S P Messier; A D Paltiel; J N Katz
Journal:  Osteoarthritis Cartilage       Date:  2018-03-02       Impact factor: 6.576

Review 8.  Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.

Authors:  R Andrew Moore; Sheena Derry; Geoffrey T Makinson; Henry J McQuay
Journal:  Arthritis Res Ther       Date:  2005-03-24       Impact factor: 5.156

9.  Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports.

Authors:  R Andrew Moore; Sheena Derry; Henry J McQuay
Journal:  Arthritis Res Ther       Date:  2008-05-08       Impact factor: 5.156

10.  Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.

Authors:  Roy Fleischmann; Hyman Tannenbaum; Neha P Patel; Marianne Notter; Peter Sallstig; Jean-Yves Reginster
Journal:  BMC Musculoskelet Disord       Date:  2008-03-07       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.